Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07563049

Possible Augmentation Of NB-UVB Induced Pigmentation In NSV By Carboxy.

Patients with stable vitiligo with 2 or more symmetric patches, 2 on acral sites and/or 2 on non acral sites will be recruited and assessed for eligibility for inclusion to receive NB-UVB on the whole body, and carboxytherapy on one randomized side.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Vitiligo Vulgaris Hypopigmentation Pigmentation Disorders Skin Diseases Skin and Connective Tissue Diseases Vitiligo

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Faculty of Medicine, Cairo University

Cairo, El Manial, 11956, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects with stable non-segmental vitiligo (≥2 symmetrical patches of diameter less than 2 cm on acral or ≥ 2 symmetrical patches on non-acral sites). Subjects were stable for twelve or more months.

Exclusion criteria

  • Subjects with unstable vitiligo.
  • Subjects with segmental vitiligo.
  • Pregnant females.
  • Severe anemia (Hb <7 gm/dl).
  • Cardiac/hepatic/renal/respiratory failure.
  • Superficial thrombophlebitis.
  • Subjects with history of skin malignancy or precancerous conditions like Xeroderma pigmentosum.
  • Subjects with other autoimmune disorders.
  • Systemic drugs for vitiligo in the last 3 months.

Treatment and study plan

NB-UVB alone

Device

Narrow-Band Ultraviolet B phototherapy full cabin

NB-UVB combined with carboxy

Device

Narrow-Band Ultraviolet B phototherapy full cabin combined with Intradermal injection of carbon dioxide gas

Primary outcomes

  1. Vitiligo Extent Score for a Target Area (VESTA)

    Time frame: 6 months- 1 year

    Assessment of the treatment response in a target area Range 0-100%

  2. Estimation of human E-Cadherin using ELISA

    Time frame: 6 months -1 year

  3. Estimation of malondialdehyde by spectrophotometer

    Time frame: 6 months-1 year

Secondary outcomes

  1. Patients' global satisfaction

    Time frame: 6 months -1 year

    five-point grading scale

    -1-3

Sponsors and collaborators

Lead sponsor

Kasr El Aini Hospital

Other

Registry information

Official study title

Evaluation Of Carboxytherapy As An Adjuvant To Narrowband-Ultraviolet B Phototherapy For The Treatment Of Stable Non-Segmental Vitiligo: A Clinical And Biochemical Study .

Acronym: NB-UVB

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
May 1, 2026
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.